Rigel Pharmaceuticals Appoints Commercial Veteran Michael P. Miller to Boost Portfolio Growth

Commercial veteran joins Rigel’s board to steer portfolio growth

Rigel Pharmaceuticals appoints Michael P. Miller to its board, naming a commercial executive with more than four decades of industry experience to help execute the company’s strategic plan. The South San Francisco-based biotech says Miller’s background in commercial leadership will support objectives to grow its marketed portfolio and to evaluate potential in‑licensing opportunities that can expand its offerings for hematologic disorders and cancer. Raul Rodriguez, Rigel’s president and chief executive, says the hire is aimed squarely at strengthening commercial execution as the company advances its development pipeline.

Miller brings a lengthy track record in commercial roles across biopharma, most recently serving as executive vice president for U.S. commercial at Jazz Pharmaceuticals until his retirement in 2020. His prior positions include chief commercial officer roles at Vivus and Connetics (later acquired), leadership of the HER Family oncology franchise at Genentech, and earlier commercial posts at ALZA and Syntex. He also serves on the boards of Puma Biotechnology and BioXcel Therapeutics, and holds a B.S. in business administration and finance and an M.B.A. in information and computer systems from San Francisco-area universities.

Miller says he views Rigel as a “profitable company with a strong commercial engine” that can fund a promising development program, and he is “thrilled to join Rigel as a Director” to help expand patient access to therapies. The appointment signals Rigel’s intent to pair clinical development with an enhanced commercialization strategy, using board-level experience to prioritize assets and potential partnerships that can accelerate patient reach and revenue generation.

Company background and messaging

Founded in 1996, Rigel markets products and advances a pipeline of potential therapies, with a stated focus on discovering and developing novel treatments that improve lives worldwide. The company frames the board addition as part of a broader transformation to balance near-term commercial growth with long‑term development programs in hematology and oncology.

The announcement is distributed from Rigel’s South San Francisco headquarters via PR Newswire and includes investor and media contact details. Company representatives position the move as strengthening governance and commercial capability as Rigel pursues licensing and product expansion opportunities.